Serum calprotectin levels: A measure of disease activity in rheumatoid arthritis
Objectives: RA affects about 1% of adults in developed countries and prevalence is found to be three times more in women than men. RA is a leading cause of disability worldwide and it is estimated that up to 70% of patients with RA experience disability within 10 years of disease onset. Calprotectin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Muller Journal of Medical Sciences and Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/mjmsr.mjmsr_54_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objectives:
RA affects about 1% of adults in developed countries and prevalence is found to be three times more in women than men. RA is a leading cause of disability worldwide and it is estimated that up to 70% of patients with RA experience disability within 10 years of disease onset. Calprotectin is a damage-associated molecular pattern protein and reflects mainly neutrophil activation. It is released due to the accumulation of macrophages and fibroblast-like synoviocytes in the joints in RA patients; thus, it is suggested to be a good alternative to acute-phase protein as a biomarker in RA due to its presence near the site of cartilage destruction and bone erosion. The aim of this study was to investigate the association of serum calprotectin with disease severity in RA.
Methods:
The present study was an observational and cross-sectional study conducted on 75 diagnosed patients who were subgrouped into high, moderate, low, and remission according to DAS28 score of disease severity. C-reactive protein (CRP) and rheumatoid factor (RF) were estimated along with routine investigations by immunoturbidimetric method. Serum anti-cyclic citrullinated peptide (CCP) and serum calprotectin levels were measured by enzyme-linked immunosorbent assay. The data were compared among different subgroups by appropriate statistical tools using the IBM SPSS 25.0 software.
Results:
Levels of serum calprotectin showed a statistically significant difference in different subgroups based on DAS28 score (P < 0.05). However, RF and anti-CCP did not show a significant difference with an increase in disease activity. A significant positive correlation of serum calprotectin was found with CRP, erythrocyte sedimentation rate, RF, and anti-CCP and DAS28 score (P < 0.05). Serum calprotectin was found to be the best predictor of active disease based on DAS28 at a cutoff point of >10.53 μg/mL with an area under the curve of 0.969.
Conclusion:
The results suggest that serum calprotectin is a significant marker to assess disease activity in RA. However, further studies with larger sample size would be required to validate the findings. |
|---|---|
| ISSN: | 0975-9727 2321-3701 |